McCollum Christoferson Group Q2 2026 Portfolio Activity Analysis

As reported in their latest filing dated June 30, 2026, McCollum Christoferson Group Llc has shown active portfolio management this quarter. The investment firm appears to have focused on specific sectors while strategically adjusting its holdings.

The investor's overall portfolio value stands at $340,744,399 as of June 30th. Their allocation strategy involves diversification across various industries and sectors, with Technology being the largest sector represented in their current portfolio.

Significant Purchases This Quarter

In a notable move during Q2 2026, McCollum Christoferson Group Llc significantly increased its stake in several companies:

• IBM (Technology): The investor added shares to this technology giant, resulting in a nearly 1089% increase in position size. This suggests strong confidence or anticipation regarding the company's prospects.
• XLI: Shares of this ETF were newly acquired by the investor, representing an immediate 100% jump in allocation for a total value of $5.8 million.
• IBB (iShares Biotechnology ETF): This sector-specific ETF saw its full position created this quarter, indicating an entry into the healthcare innovation space with a 100% allocation increase.
• PAVE: Shares of this Global X Infrastructure Development ETF were also newly acquired by McCollum Christoferson Group Llc, establishing a fresh position worth $3.0 million.

These purchases signal the investor's interest in specific technology sub-sectors and infrastructure-related themes during the second quarter.

Strategic Sales and Portfolio Adjustments

Concurrently, McCollum Christoferson Group Llc reduced its exposure to certain areas:

• MTB: The investor sold shares of this financial services holding, leading to a 68.73% reduction in position size and lowering the allocation from approximately 1.25% down to 0.72%. This significant decrease suggests a strategic shift away from this particular bank.
• TSCO (Tractor Supply Co): The investor exited their position entirely in TSCO, reducing the allocation to zero. This indicates a complete divestment of this consumer cyclical stock.
• ABT (Abbott Laboratories): The investor significantly decreased their stake in healthcare company Abbott, resulting in a 60.69% reduction and lowering the allocation to just 0.09%. This suggests either profit-taking or a shift away from this specific pharmaceutical stock.

The combination of these sales alongside new purchases points towards a dynamic investment approach focused on capitalizing on perceived value changes across different market segments.

Overall Portfolio Changes and Patterns

This quarter, McCollum Christoferson Group Llc's portfolio saw an increase in the number of holdings from 79 to potentially more than 80 (as some exited positions may not be listed). The top five holdings by weight accounted for approximately 26.46% of the total portfolio value.

The investor has demonstrated both buying and selling activities, with significant purchases noted in IBM, XLI, IBB, PAVE, and substantial sales involving MTB, TSCO, and ABT. This pattern of activity suggests ongoing monitoring and adjustment based on market opportunities or performance expectations.

For further details on McCollum Christoferson Group Llc's investment activities, you can visit their institutional profile. Detailed information about each stock held or sold is available through the respective links provided.